Discover details of Bristol-Myer Squibbs latest immuno-oncology drug deal, DiaCarta’s funding into its diagnostic platform and Cancer Research UK’s pledge to invest £45 million into clinical trials.
Browsing: Taxonomy > Immunotherapy
Delve deeper into the promising PD-L1 research being published, in this patient perspective piece from Stage IV melanoma patient T.J. Sharpe.
This review summarizes the past decade of immunotherapy for non-small-cell lung cancer, gives an updated overview of trials in this field, and the context of future development in this exciting field.
Data from the CheckMate-227 trial has demonstrated that its cancer drug combination has reached its primary endpoint of progression-free survival.
The American Society of Clinical Oncology (ASCO) has named adoptive cell immunotherapy as their clinical cancer Advance of the Year.
Recently at the 2018 ASCO-SIC Clinical immune-oncology symposium (CA, USA, 25-27 January) a panel discussed the science presented in a…
Results of a Phase I study have suggested multisite stereotactic body radiotherapy prior to immunotherapy treatment may improve patient outcomes.
A Phase I trial using a combination of immunotherapy drugs has demonstrated promise for the treatment of advanced solid tumors .
Findings presented at the 2018 ASCO-SITC symposium highlight initial success for a new form of CAR T-cell treatment.